GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-13 and is reviewed periodically as new material appears.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Regulation This pathway undergoes transcriptional regulation by FadR and FabR. FadR is the more extensively studied protein and has been attributed bifunctional characteristics. It acts as an activator of fabA and fabB transcription and as a repressor for the β-oxidation regulon. In contrast, FabR acts as a repressor for the transcription of fabA and fabB.
5G cellular network – next-generation cellular networks which began deployment in 2019. Their major advantage is much higher data rates than previous cellular networks, up to 10 Gbps; 100 times faster than the previous cellular technology, 4G LTE. The higher data rates are achieved partly by using higher frequency radio waves, in the higher microwave band 3–6 GHz, and millimeter wave band, around 28 and 39 GHz. Since these frequencies have a shorter range than previous cellphone bands, the cells will be smaller than the cells in previous cellular networks which could be many miles across. Millimeter-wave cells will only be a few blocks long, and instead of a cell base station and antenna tower, they will have many small antennas attached to utility poles and buildings.
the Sai Kung Volcanic Rock Region, with its widely distributed tuff volcanic rocks displaying prismatic columnar jointing, which are of international geological significance the Northeast New Territories Sedimentary Rock Region, which comprises sedimentary rocks formed in different geologic periods, showcasing the complete geological history of Hong Kong.
Sources: en.wikipedia.org
==== 2700–2799 ==== Social Security (Introduction of Disability Living Allowance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/2704) Capital Allowances (Corresponding Northern Ireland Grants) Order 1993 (S.I. 1993/2705) Building Societies (Designation of Qualifying Bodies) (No. 3) Order 1993 (S.I. 1993/2706) Education (No. 2) Act 1986 (Amendment) Order 1993 (S.I. 1993/2709) Housing Renovation etc. Grants (Grant Limit) (Amendment) Order 1993 (S.I. 1993/2711) Reconstitution of the River Ouzel Internal Drainage Board Order 1993 (S.I. 1993/2712) Placing on the Market and Supervision of Transfers of Explosives Regulations 1993 (S.I. 1993/2714) Food Labelling (Scotland) Amendment Regulations 1993 (S.I. 1993/2731) Teachers (Education, Training and Recommendation for Registration) (Scotland) Regulations 1993 (S.I. 1993/2732) Portsmouth Mile End Quay (Berth No. 2 Extension) Harbour Revision Order 1993 (S.I. 1993/2733) Criminal Justice Act 1993 (Commencement No. 3) Order 1993 (S.I. 1993/2734) Social Security (Contributions) (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/2736) Public Service Vehicles (Registration of Local Services) (Amendment) Regulations 1993 (S.I. 1993/2752) Public Service Vehicles (Operators' Licences) (Amendment) Regulations 1993 (S.I. 1993/2753) Public Service Vehicles (Traffic Commissioners: Publication and Inquiries) (Amendment) Regulations 1993 (S.I. 1993/2754) Copyright (Certification of Licensing Scheme for Educational Recording of Broadcasts) (Open University Educational Enterprises Limited) Order 1993 (S.I.
Ca(OH)2 + x/8 S8 → CaSx + by-products (S2O2−3, SO2−3, SO2−4) as reported in a document of the US Department of Agriculture (USDA). This reaction is poorly understood because it is vague and involves the reduction of elemental sulfur, and no reductant appears in the equation, while sulfur oxidation products are also mentioned. The initial pH of the solution imposed by poorly soluble hydrated lime is alkaline (pH = 12.5) while the final pH is in the range 11–12, typical for sulfides, which are also strong bases. When the hydrolysis of calcium sulfide is taken into account, the individual reactions for each of the by-products are:
==== Movies ==== Fantasia (1940), with lead visualist Oskar Fischinger, may have been inspired by mescaline-induced visuals. Fear and Loathing in Las Vegas (1998) starring Johnny Depp and Benicio del Toro featured mescaline use. The Matrix (1999) by the Wachowskis included a brief mention of mescaline. The Royal Tenenbaums (2001) features a character named Eli Cash (Owen Wilson) who regularly takes mescaline. Crystal Fairy & the Magical Cactus (2013) starring Michael Cera and Gaby Hoffmann was about taking mescaline in the form of the San Pedro cactus.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.